Hacettepe Üniversitesi Hastaneleri'nde Takip Edilen Metastatik Renal Hücreli Kanser Hastalarının Sağkalımlarının Zaman Içinde Değişiminin Incelenmesi

Abstract

Data from the hospital charts of adult renal cell cancer (RCC) patients treated between January 2003 and December 2012 were analyzed using the Hacettepe University Cancer Registry Unit database. Demographic and clinical findings along with patient, tumor, treatment related prognostic factors , progression free survival, and overall survival were analyzed. A total of 305 RCC patient (209 male, 96 female) were included in the analysis. Mean age was 55.4±12.2 years. 176 patients (57.7%) developed distant metastasis. 107 (60.2%) of metastatic patients received at least one dose of IFN-α. 74 (41.5%) of metastatic patients received at least one targeted therapy. With in the targeted therapy group, 51 (28.4%) patients received sunitinib, 16 (7.4%) patients received pazopanib, 17 (9.7%) patients received sorafenib, and 27 (14.8%) patients received everolimus. Median follow-up was 19.1 months (range 1-97 months) and median overall survival was 24.6 months (95% CI, 20.4-28.9). Median overall survival of patients who received targeted therapy was significantly better compared to who not received ( 29.1 months (95% CI, 21.4-36.8) versus 19.4 months (95% CI, 14.2-24.6 month); p=0,036). 2-year overall survival was significantly better for targeted therapy; 59% versus 42%,respectively (p=0,036). The introduction of targeted therapy in metastatic RCC treatment was at 2007. Median overall survival of patients which was metastatic before 2007 do not differ from the patients which was metastatic after 2007 (24.6 months (95% CI, 16.9-32.4 months) versus 25.6 months (95% CI, 19.3-31.8 months;p=0,99), respectively. The study period of 2003-2012 was subdivided into 4 consecutive groups. Although not statistically significant a trend toward better survival was associated with progressing years and targeted therapy usage (p=0,09). Patients who received targeted therapy lived longer compared to who did not received. Especially patients in the intermediate and poor risk Memorial Sloan-Kettering Cancer Center (MSKCC) groups were benefited more from targeted vii therapies. Trend toward better survival was associated with progressing years and targeted therapy usage. Results indicate that targeted therapy is an effective treatment in RCC.